914 related articles for article (PubMed ID: 31258539)
1. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
2. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia.
Marín Oyarzún CP; Glembotsky AC; Goette NP; Lev PR; De Luca G; Baroni Pietto MC; Moiraghi B; Castro Ríos MA; Vicente A; Marta RF; Schattner M; Heller PG
Front Immunol; 2020; 11():705. PubMed ID: 32425934
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.
Bekendam RH; Ravid K
Front Cell Dev Biol; 2023; 11():1207395. PubMed ID: 37457287
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic disease in the myeloproliferative neoplasms.
Falanga A; Marchetti M
Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
[TBL] [Abstract][Full Text] [Related]
6. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
7. The Role of Leukocytes in Myeloproliferative Neoplasms Thromboinflammation.
Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
J Leukoc Biol; 2024 Mar; ():. PubMed ID: 38527797
[TBL] [Abstract][Full Text] [Related]
8. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Bhuria V; Baldauf CK; Schraven B; Fischer T
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
[TBL] [Abstract][Full Text] [Related]
9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
10. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.
Ferrer-Marín F; Cuenca-Zamora EJ; Guijarro-Carrillo PJ; Teruel-Montoya R
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498945
[TBL] [Abstract][Full Text] [Related]
11. The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
Catani L; Cavo M; Palandri F
Cells; 2021 Sep; 10(9):. PubMed ID: 34571965
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
Ball S; Thein KZ; Maiti A; Nugent K
J Thromb Thrombolysis; 2018 May; 45(4):516-528. PubMed ID: 29404876
[TBL] [Abstract][Full Text] [Related]
13. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
Reeves BN; Beckman JD
Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
[TBL] [Abstract][Full Text] [Related]
14. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.
Marković D; Maslovarić I; Djikić D; Čokić VP
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163413
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. Experimental Modeling of Myeloproliferative Neoplasms.
Lanikova L; Babosova O; Prchal JT
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31618985
[TBL] [Abstract][Full Text] [Related]
18. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
19. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
[TBL] [Abstract][Full Text] [Related]
20. Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin.
Ross DM; Liang HPH; Iqra Z; Whittaker S; Tan CW; Dale BJ; Chen VM
Sci Rep; 2023 Jun; 13(1):9172. PubMed ID: 37280424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
